Xiaoxi Wang

ORCID: 0000-0002-2232-8504 · 3 papers in corpus
observational 2024
PD-L1 expression in ovarian clear cell carcinoma using the 22C3 pharmDx assay
Diagnostic pathology ·doi:10.1186/s13000-024-01510-4

BACKGROUND: Ovarian clear cell carcinoma (OCCC), well known for its chemoresistance to platinum-based chemotherapy, exhibited a good response in clinical trials of anti-PD-1/PD-L1 inhibitors. By assessing PD-L1 expression, we sought to dete…

lab-animal 2023
Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures
Cell & bioscience ·doi:10.1186/s13578-023-01087-3

The two most prevalent subtypes of epithelial ovarian carcinoma (EOC) are ovarian clear cell carcinoma (OCCC) and high-grade serous ovarian carcinoma (HGSC). Patients with OCCC have a poor prognosis than those with HGSC due to chemoresistan…

lab-animal 2022
Inhibiting effect of miR-29 on proliferation and migration of uterine leiomyoma via the STAT3 signaling pathway
Aging ·doi:10.18632/aging.203873

AIM: Uterine leiomyoma is the most common benign tumor of female genitalia, and the incidence is rising gradually. This study explores the mechanism of miR-29 and STAT3 signaling pathways on uterine leiomyoma. METHODS: GSE64763 and GSE5244…